Share on StockTwits

CVS Caremark (NYSE:CVS) SVP Andrew Sussman sold 9,020 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $79.45, for a total transaction of $716,639.00. Following the sale, the senior vice president now directly owns 6,305 shares of the company’s stock, valued at approximately $500,932. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of CVS Caremark (NYSE:CVS) traded up 0.79% on Wednesday, hitting $80.36. 3,512,277 shares of the company’s stock traded hands. CVS Caremark has a 52 week low of $56.32 and a 52 week high of $80.62. The stock’s 50-day moving average is $78.33 and its 200-day moving average is $75.81. The company has a market cap of $93.218 billion and a price-to-earnings ratio of 19.55.

CVS Caremark (NYSE:CVS) last released its earnings data on Tuesday, August 5th. The company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.03. The company had revenue of $34.60 billion for the quarter, compared to the consensus estimate of $33.47 billion. During the same quarter in the previous year, the company posted $0.97 earnings per share. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. Analysts expect that CVS Caremark will post $4.49 EPS for the current fiscal year.

A number of analysts have recently weighed in on CVS shares. Analysts at Zacks reiterated a “neutral” rating on shares of CVS Caremark in a research note on Tuesday, August 12th. They now have a $82.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of CVS Caremark in a research note on Wednesday, August 6th. They now have a $91.00 price target on the stock, up previously from $82.00. Finally, analysts at Cantor Fitzgerald raised their price target on shares of CVS Caremark from $66.00 to $71.00 in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. CVS Caremark presently has a consensus rating of “Buy” and an average price target of $78.90.

CVS Caremark Corporation (NYSE:CVS), together with its subsidiaries, is a pharmacy health care provider in the United States.

Receive News & Ratings for CVS Caremark Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Caremark Co and related companies with Analyst Ratings Network's FREE daily email newsletter.